ProQR Therapeutics N.V. (PRQR:NASDAQ) closed at $1.38 on November 9, 2026, up 2.22% on the day. The stock trades 44.5% below its 52-week high of $2.49 and 15.0% above its 52-week low of $1.20. Over the past year, it lost 39.2%. ProQR Therapeutics N.V. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 7, 2025, PRQR closed higher on 107 days (42%). Its best day was June 29, 2026 (+19.61%) and its worst was January 9, 2026 (-15.71%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 2 times.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The company's clinical stage candidates include QR-010, a RNA-based oligonucleotide that is in Phase Ib clinical trial for the treatment of cystic fibrosis. It also develops QR-110, which is in pre-clinical development stage for the treatment of Leber's congenital amaurosis. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
Find more stocks like PRQR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.